DISCOVER ACHILLES
ADVANCING IN THE CHALLENGE OF IMPROVING LYMPHOMA AND LEUKEMIA SURVIVAL
ACHILLES is a Marie Skłodowska Curie Action (MSCA) Doctoral Network (DN) funded by the European Commission under Horizon Europe program.
ACHILLES will deliver high level multidisciplinary training in experimental hemato-oncology to 16 Doctoral Candidates (DCs), equipping them with a deep understanding of the full translational pathway from fundamental biological discoveries to the development of innovative therapeutic strategies and diagnostic tools that directly impact leukemia and lymphoma patients.
ACHILLES DCs will train across 15 institutions in 12 European countries, within a network further strengthened by the involvement of biotechnology and drug discovery partners as well as the European Hematology Association (EHA) and the European School of Hematology (ESH).
The ACHILLES program focuses on three core scientific objectives: building the capacities of hemato-oncology research with innovative experimental models and advanced analytical tools; generating knowledge to deepen our understanding of the molecular mechanisms driving leukemia and lymphoma; and transferring new technologies through the development of targeted drugs and advanced therapies for patients with hematological malignancies.
Leveraging state-of-the-art technologies, including innovative experimental models, multi-omics approaches, computational modeling, and artificial intelligence, ACHILLES aims to enhance diagnostics, predict treatment responses, and optimize therapeutic strategies in hemato-oncology.
With a patient-centered mission, ACHILLES bridges research, clinical practice, and innovation, advancing Europe’s Beating Cancer Plan and driving improved outcomes for patients across Europe and beyond.
NEWS
01.12.2025
The ACHILLES Consortium is pleased to announce the official Kick-Off of the project will take place on December 1st, 2025, marking the start of this collaborative European initiative.
